Indaptus Therapeutics
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3 Columbus Cir Fl 15, New York City, New...Phone Number
(646) 427-2727Website
www.indaptusrx.comRevenue
-Stock Symbol
INDPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York City, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's approach leverages the body's innate and adaptive immune systems by utilizing engineered, non-pathogenic gram-negative bacteria to activate multiple immune pathways.Explore more
Indaptus Therapeutics Org Chart
JM
Co-Chief Executive Officer
YD
Chief Financial Officer
DL
Co-Chief Executive Officer & Chairman of the ...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Indaptus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Indaptus Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Indaptus Therapeutics recently announced quarterly report
Product Launch: Get notified when Indaptus Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Indaptus Therapeutics
Funding: Get notified immidiatlly once Indaptus Therapeutics has new funding data
Check out if Indaptus Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Indaptus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Indaptus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Indaptus Therapeutics
Find 2 more new buyers
Compare Similar Companies to Indaptus Therapeutics
Compare insights from companies similar to Indaptus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$81.2M
2008
MP
Marilena PerroneResearch & Development Operations Manager, Project Management
Company Profile Activity
Activity Insights
Indaptus Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Indaptus Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Indaptus Therapeutics.
Indaptus Therapeutics financials insights
Gather financial insights about Indaptus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$2.3M
Indaptus Therapeutics Tech Stack
A closer look at the technologies used by Indaptus Therapeutics
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Indaptus Therapeutics News & Media
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update.Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026
Indaptus Therapeutics, Inc. - Executive Changes and Board Updates (8-K Filing) Indaptus Therapeutics, Inc. Announces Significant Executive and Board Changes Key Points: Appointment of Yu Ding as Chief Financial Officer, effective April 1, 2026. Resignation of Matthew McMurdo from the Audit Committee. Appointment of Qinglai Lu and Jerome Abbour to the Audit Committee. Yu Ding...Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus’ Co-Chief Executive Officer and Chairman of thIndaptus Therapeutics Inc appoints David Lazar as co-chief executive officer
Indaptus Therapeutics Inc: Indaptus Therapeutics Inc - appointed David Lazar as the co-chief executive officer ...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Indaptus Therapeutics
Sign Up For FreeTo access detailed company insights
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York City, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's approach leverages the body's innate and adaptive immune systems by utilizing engineered, non-pathogenic gram-negative bacteria to activate multiple immune p... Read More
